Evolent Health, Inc. is a specialty care management company that provides clinical decision support, provider network management, and administrative services to health plans and risk-bearing entities. Founded in 2011 by UPMC and The Advisory Board Company, the firm focuses on complex conditions including oncology, cardiology, musculoskeletal disorders, radiology, and genetics. Its primary solution, Specialty Care Management Services, utilizes proprietary technology to design evidence-based clinical pathways and assemble high-performance provider networks to improve care quality and reduce costs. The company also offers administrative services, including health plan administration, pharmacy benefit management, and risk management, through its integrated value-based care platform. Evolent serves customers in the United States, with a workforce operating in the U.S., India, and the Philippines. Key subsidiaries and acquired entities include New Century Health and Evolent Care Partners, the latter of which was sold in December 2025. The company employs clinical staff, including physicians and nurses, to support provider engagement and patient navigation.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Health Information Services Homepage evolent.com
Sector Healthcare IR page ir.evolent.com
Tags
specialty care management, clinical pathways, oncology, cardiology, musculoskeletal, radiology, genetics, health plan administration, pharmacy benefit management, value-based care, provider network management, CarePro, Identifi, New Century Health, Evolent Care Partners, UPMC, The Advisory Board Company
Press page ir.evolent.com/news

Metrics

Valuation  
Market cap $ 394.738M
Market cap (USD) $ 394.738M
P/E -0.78
PEG —
P/BV 1.06
P/S 0.17
P/OCF 6.08
P/FCF 83.02
Dividend yield 0.29%
Turnover / mcap —
Returns  
ROE -75.5%
ROI -38.6%
ROIC -22.2%
Profit margin -28.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock Yes
Diluting (TTM) Yes
Debt/Equity 260.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score -55.6%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 1.876B 2.555B 1.964B 1.352B 907.957M 1.022B 846.383M 627.063M 434.95M 254.188M 96.878M 0
Net profit -534.51M -61.623M -113.04M -19.164M -37.601M -334.246M -301.971M -52.658M -60.665M -159.742M 332.494M -25.246M
Free cash flow 4.755M -6.128M 113.837M -49.914M 13.764M — -78.179M -60.201M -55.806M -51.036M -24.983M 0

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 4 11.25 33.03 28.08 27.67 16.03 9.05 19.95 12.3 14.8 12.11 —
Price performance 12m -0.64 -0.66 0.18 0.01 0.73 0.77 -0.55 0.62 -0.17 0.22 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 40.6M 48.9M 80.2M 75.7M 126M 131M 255M 447M 415M 310M
↳ YoY growth +99.4% +20.5% +63.9% -5.7% +66.5% +3.7% +95.0% +75.4% -7.2% -25.3%
↳ 5y CAGR +44.0% +26.3% +39.1% +41.0% +40.5% +19.7%
Borrowings, current (USD) — — — 0.00 26.6M 0.00 0.00 0.00 171M 0.00
Borrowings, non-current (USD) — — — 294M 263M 216M 413M 597M 491M 971M
Lease liabilities (USD) — — 0.00 75.1M 69.9M 64.8M 63.1M 47.7M 51.7M 19.2M
Cash and deposits (USD) 135M 238M 228M 101M 340M 266M 188M 193M 104M 152M
Intangible assets (USD) 259M 241M 335M 308M 268M 280M 443M 752M 680M 585M
Right-of-use assets (USD) — — 0.00 72.2M 57.8M 50.2M 49M 12M 6.13M 4.37M
Net debt (borrowings + leases - cash) (USD) — — — 268M 19.3M 14.2M 288M 452M 609M 838M
Cash flow detail
Operating cash flow (USD) -35.5M -28M -20.7M -42.6M -16.2M 38.7M -11.6M 143M 18.8M 38.8M
Purchases of property, plant and equipment (USD) -15.5M -27.8M -39.6M -35.5M — — — — — —
Change in receivables (cash effect) (USD) -11M -11.3M — — — — — — — —
Change in payables (cash effect) (USD) -6.37M 5.56M 7.6M -5.48M 3.55M 7.25M 13.2M -6.72M 4.25M 6.64M
Share buybacks (cash effect) (USD) — — — — — — — 0.00 0.00 -40M
Interest paid (cash effect) (USD) 0.00 -2.47M -2.5M -5.04M -13.4M -7.11M -6.27M — — —
Income taxes paid (cash effect) (USD) 0.00 -674,000 -343,000 -1.48M -9.68M -551,000 -1.4M -4.89M -1.39M -2.6M
Share-based compensation (USD) 18.6M 20.4M 17.6M 15.6M 14.6M 16.7M 34M 40.5M 39.7M 39.7M
Operating cash flow before change in receivables (USD) -24.5M -16.7M — — — — — — — —
Free cash flow (OCF - PPE - intangibles) (USD) -51M -55.8M -60.2M -78.2M — — — — — —
Income detail
Research and development expense (USD) 11.1M 17.2M 18.2M 19.8M 15.1M 15.5M — — — —
↳ 5y CAGR +55.5% +21.1% +6.9%
Total comprehensive income (USD) -227M -69.8M -54.4M -306M -334M -37.7M -20M -142M -94M -580M
Comprehensive income to owners (USD) -160M -60.7M -52.8M -302M -334M -37.7M -20M -142M -94M -580M
Provision for credit losses (USD) — — — — 3.28M 2.41M 2.74M 10.8M 4.8M 8.88M
Credit cost ratio (credit losses / average receivables) (%) — — — — 3.3% 1.9% 1.4% 3.1% 1.1% 2.5%
Reported Feb 28, 2019 Feb 28, 2019 Mar 2, 2020 Feb 26, 2021 Feb 26, 2021 Feb 24, 2022 Nov 2, 2023 Feb 25, 2026 Feb 25, 2026 Feb 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Evolent Announces Third Quarter 2026 Results Bull 5 Bear 0 Results

WASHINGTON, Nov. 5, 2026 /PRNewswire / -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended September 30, 2026.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us. That growth and demand from existing clients, as well as strong execution in our 2026 oncology launches, continue to drive strong performance in 2026. Looking ahead, I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come."

Highlights include (in thousands, except for average PMPM fees and revenue per case):

For the Three Months Ended September 30,
2026 2025
Financial Results:
Revenue $  725,367 $  479,533
Net loss attributable to common shareholders of Evolent Health, Inc. $   (23,566) $   (26,930)
Net loss margin (3.2) % (5.6) %
Adjusted EBITDA $    34,257 $    38,955
Adjusted EBITDA Margin 4.7 % 8.1 %
Average Lives on Platform/Cases
Performance Suite 7,195 6,474
Specialty Technology and Services Suite 74,733 78,050
Administrative Services 1,163 1,222
Cases 11 13
Average Unique Members 39,804 40,781
Average PMPM Fees/ Revenue per Case
Performance Suite $      26.14 $      14.77
Specialty Technology and Services Suite 0.32 0.40
Administrative Services 13.84 15.77
Cases 3,605 3,236
Medical Expense Ratio 93.0 % 85.0 %
Medical Expense Ratio excluding Evolent Care Partners N/A 91.9 %

The rising medical costs impacting health plans continue to drive robust demand for Evolent's complex specialty care solutions.

Evolent announced one renewal and two new revenue agreements, bringing the year-to-date total to seven:

  • First, we renewed our largest Surgical Management customer contract for an additional four years. Surgical Management is the IPG business acquired by Evolent in 2022. We believe this multi-year commitment from a long-standing partner reinforces the value of our model and the strength of our client relationships.

  • Second, we are expanding our relationship with an existing client to provide oncology services across several additional states, representing approximately 1 million Commercial lives, with a January 1, 2027 go-live. The agreement also adds Member Navigation across all existing and new lives, broadening the relationship beyond the client's existing solution and demonstrating our opportunity to drive growth through expanded adoption of Evolent's solutions.

  • Third, we expanded our relationship with a national payer in Specialty Technology & Services for oncology across 11 additional states. 

Financial Results of Evolent Health, Inc.

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss financial measures not prepared in accordance with generally accepted accounting principles ("GAAP"). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See "Non-GAAP Financial Measures" for more information.

Reported Results

Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):

For the Three Months Ended September 30,
2026 2025
Revenue $     725,367 $  479,533
Cost of revenue 636,946 379,759
Selling, general and administrative expenses 73,116 77,592
Net loss attributable to common shareholders of Evolent Health, Inc. (23,566) (26,930)
Net loss margin (3.2) % (5.6) %
Loss per share attributable to common shareholders of Evolent Health, Inc.
Basic and diluted $         (0.21) $     (0.24)

Total cash and cash equivalents was $148.3 million as of September 30, 2026.

Adjusted Results

Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):

For the Three Months Ended September 30,
2026 2025
Adjusted cost of revenue $  635,107 $   378,518
Adjusted selling, general and administrative expenses $    56,003 $    62,060
Adjusted EBITDA $    34,257 $    38,955
Adjusted EBITDA margin 4.7 % 8.1 %
Adjusted income attributable to common shareholders $      7,296 $      5,630
Adjusted income per share attributable to common shareholders:
Basic and diluted $       0.06 $       0.05

Business Outlook   

The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include change in tax receivable agreement liability, other refinancing fees, income (loss) from equity method investees, gain (loss) on repayment/extinguishment of debt, other income (expense), gain (loss) on disposal of non-strategic assets, goodwill impairments, right-of-use asset impairments, gain (loss) on lease terminations, stock-based compensation expense, severance costs and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.

Full Year 2026 Guidance

Incorporating its year-to-date performance, the Company is reiterating its 2026 revenue guidance range to $2.6 billion to $2.7 billion and raising its Adjusted EBITDA range to $130.0 million to $135.0 million.

Additional Outlook Information

The Company expects to deploy $26 million to $28 million in cash for capitalized expenditures during 2026.

This "Business Outlook" section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations in addition to those set forth above are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").

Web and Conference Call Information

Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this morning, November 5, 2026, at 8:30 a.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http://ir.evolent.com . To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the "Evolent Health call." Participants are advised to dial in at least fifteen minutes prior to the call to register. An audio playback of the conference call will be available on Evolent's investor relations website for 90 days after the call. Evolent invites all interested parties to attend the conference call.

Evolent Health Logo

About Evolent 

Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.

Evolent Announces Second Quarter 2026 Results Bull 5 Bear 0 Results

WASHINGTON, Aug. 6, 2026 /PRNewswire / -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2026.

Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow. We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure."

Mario Ramos, Chief Financial Officer of Evolent stated, "Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026. We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150 million driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition. We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility."

Highlights include (dollars in thousands, except for average PMPM fees and revenue per case):

For the Three Months Ended June 30,
2026 2025
Financial Results:
Revenue $     652,520 $      444,328
Net loss attributable to common shareholders of Evolent Health, Inc. $      (28,364) $       (51,090)
Net loss margin (4.3) % (11.5) %
Adjusted EBITDA $       28,050 $        37,547
Adjusted EBITDA Margin 4.3 % 8.5 %
Average Lives on Platform/Cases by Product Type
Performance Suite 6,715 6,490
Specialty Technology and Services Suite 75,641 77,019
Administrative Services 1,189 1,231
Cases 12 13
Average Unique Members 39,956 40,201
Average PMPM Fees/ Revenue per Case by Product Type
Performance Suite $         24.05 $        13.76
Specialty Technology and Services Suite 0.34 0.35
Administrative Services 13.46 15.13
Cases 3,608 2,969
Medical Expense Ratio 95.3 % 80.0 %
Medical Expense Ratio excluding Evolent Care Partners 95.3 % 84.9 %

The rising medical costs impacting health plans continue to drive robust demand for Evolent's complex specialty care solutions.

Evolent has two partnership announcements, bringing the year-to-date total to four:

  • First, we are preparing for the go live of an Oncology Performance Suite partnership with an existing advanced imaging client. The partnership will cover approximately 1.5 million lives across Medicaid and Medicare populations spread through 11 states. We currently expect this business to launch by December 2026, subject to certain regulatory approvals, and generate approximately $300 million in annualized revenue. As with other recent Performance Suite arrangements, this relationship includes Evolent's full enhanced contractual protections.
      
  • Second, an existing Specialty Technology & Services Suite client, a regional Blues plan customer, has signed an agreement to broaden its use of our Specialty Technology & Services Suite by adding new products and extending existing solutions to additional populations. We expect these implementations to occur during the third and fourth quarters of this year and annualized revenue from this contract to be less than $5 million.

Financial Results of Evolent Health, Inc.

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we may use or discuss financial measures not prepared in accordance with generally accepted accounting principles ("GAAP"). Definitions of the non-GAAP financial measures as well as reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are presented herein. See "Non-GAAP Financial Measures" for more information.

Reported Results

Evolent Health, Inc. reported the following results in accordance with GAAP (dollars in thousands, except for per share data):

For the Three Months Ended June 30,
2026 2025
Revenue $     652,520 $  444,328
Cost of revenue $     571,684 $  343,943
Selling, general and administrative expenses $       68,831 $    75,209
Net loss attributable to common shareholders of Evolent Health, Inc. $      (28,364) $   (51,090)
Net loss margin (4.3) % (11.5) %
Loss per share attributable to common shareholders of Evolent Health, Inc.
Basic and diluted $         (0.25) $       (0.44)

Total cash and cash equivalents was $115.7 million as of June 30, 2026.

Adjusted Results

Evolent Health, Inc. reported the following adjusted results (dollars in thousands, except for per share data):

For the Three Months Ended June 30,
2026 2025
Adjusted cost of revenue $  570,989 $   342,893
Adjusted selling, general and administrative expenses $    53,481 $     63,888
Adjusted EBITDA $    28,050 $     37,547
Adjusted EBITDA margin 4.3 % 8.5 %
Adjusted income (loss) attributable to common shareholders $      2,226 $    (11,013)
Adjusted income (loss) per share attributable to common shareholders:
Basic and diluted $       0.02 $        (0.10)

Business Outlook

The Company does not believe it can meaningfully reconcile guidance for non-GAAP Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. because the Company cannot provide guidance for the more significant reconciling items between net income (loss) attributable to common shareholders of Evolent Health, Inc. and Adjusted EBITDA without unreasonable effort. This is due to the fact that future period non-GAAP guidance includes adjustments for items not indicative of our core operations, and as a result from changes to our business due to transactions and other events. Such items may, from time to time, include change in tax receivable agreement liability, other refinancing fees, gain (loss) from equity method investees, gain (loss) on repayment/extinguishment of debt, other income (expense), gain (loss) on disposal of non-strategic assets, goodwill impairments, right-of-use asset impairments, gain (loss) on lease terminations, stock-based compensation expense, severance costs and transaction-related costs. Such adjustments may be affected by changes in ongoing assumptions, judgments, as well as nonrecurring, unusual or unanticipated charges, expenses or gains (losses) or other items that may not directly correlate to the underlying performance of our business operations. The exact amount of these adjustments is not currently determinable but may be significant.

Full Year 2026 Guidance

Incorporating its year-to-date performance, the Company is raising its 2026 revenue guidance range to $2.6 to $2.7 billion. The Company is also tightening its Adjusted EBITDA guidance range to $120 to $135 million.

Additional Outlook Information

The Company expects to deploy $25 million to $30 million in cash for capitalized software development during 2026.

This "Business Outlook" section contains forward-looking statements, and actual results may differ materially. Factors that may cause actual results to differ materially from our current expectations in addition to those set forth above are set forth below in "Forward Looking Statements - Cautionary Language" and Evolent Health, Inc.'s filings with the Securities and Exchange Commission ("SEC").

Web and Conference Call Information

Evolent Health, Inc. will hold a conference call to discuss its financial performance and related matters this morning, August 6, 2026, at 8:00 a.m., Eastern Time. To listen to a live broadcast via the internet and view the accompanying materials, please visit the Company's Investor Relations website at http://ir.evolent.com . To participate by telephone, dial (855) 940-9467, or (412) 317-6034 for international callers, and ask to join the "Evolent Health call." Participants are advised to dial in at least fifteen minutes prior to the call to register. The call will be archived on the Company's website for one week and will be available beginning later this evening. Evolent invites all interested parties to attend the conference call.

Evolent Health Logo

About Evolent

Evolent specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolent.com.

Prompts

Evolent Health, Inc (ticker EVH), listed in United States.

ETFs Holding Evolent Health, Inc

ETF Weight in ETF Shares Market value As of
JSML 0.30% 353,725 $ 1.093M Jul 31, 2026
JSMD 0.24% 814,328 $ 2.516M Jul 31, 2026
VFVA 0.09% 193,814 $ 872.163K Aug 31, 2026
SCDS 0.09% 1,791 $ 8,274.42 Nov 17, 2026
RESM 0.03% 174 $ 943.08 Jun 30, 2026
DFSV 0.01% 380,919 $ 1.817M Nov 12, 2026
DFAS 0.00% 9,582 $ 45.706K Nov 12, 2026
DFAC 0.00% 22,991 $ 109.667K Nov 12, 2026